VCM
CGEM icon

Versant Capital Management’s Cullinan Oncology CGEM Stock Holding History

Versant Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23
Closed -$173 – 2653
2025
Q2 		$173 Buy
+23
New +$185 ﹤0.01% 2602

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Versant Capital Management's CGEM Position: Q3 2025 in Review

Versant Capital Management sold out of Cullinan Oncology (CGEM) in Q3 2025, closing a stake of 23 shares — an estimated $173 sold.

Versant Capital Management first reported a position in CGEM in Q2 2025 and held it in 1 quarter. The position peaked at $173 in Q2 2025. 145 funds tracked by Wall St. Rank hold CGEM as of Q3 2025.

  • Versant Capital Management reported no remaining Cullinan Oncology position as of Q3 2025 after selling out during the quarter.
  • Versant Capital Management sold 23 Cullinan Oncology shares in Q3 2025, an estimated $173.
  • Versant Capital Management first reported a position in Cullinan Oncology in Q2 2025 and held it in 1 quarter.
  • Versant Capital Management's Cullinan Oncology position peaked at $173 in Q2 2025.
  • 145 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2025.

Based on Versant Capital Management's 13F filing for Q3 2025, filed 27 Oct 2025.